PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Войти

Зарегистрироваться
Забыли пароль?

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

DJI 0012
20180814 193101
20180812 000122
20180202 163717
20180816 145328
20180131 184310
  • Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease;Parkinson Disease;Dementia, Date of authorisation: 03/12/1998, Revision: 45, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
  • Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
  • An Update on Field Alert Reports (FAR) and Biological Product Deviation Reports (BPDR) - 05/24/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
  • Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Dementia;Alzheimer Disease;Parkinson Disease, Date of authorisation: 11/05/1998, Revision: 46, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
  • Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
  • Human medicines European public assessment report (EPAR): Amversio, betaine anhydrous, Homocystinuria, Date of authorisation: 05/05/2022, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
  • Human medicines European public assessment report (EPAR): Omvoh, mirikizumab, Colitis, Ulcerative, Date of authorisation: 26/05/2023, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
  • Human medicines European public assessment report (EPAR): Zonisamide Mylan, zonisamide, Epilepsy, Date of authorisation: 31/03/2016, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
  • FDA Compounding Quality Center of Excellence Cross-Sector Stakeholder Group
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
  • Tainted Weight Loss Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
  • Recently Issued Guidance Documents
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-06-07 By FDA
  • Administrative Guidances
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-06-07 By FDA
  • What’s New for Biologics
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-06-07 By FDA
  • Drug Shortages | Additional News and Information
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-07 By FDA
  • FDA updates on hand sanitizers consumers should not use
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-07 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.